Literature DB >> 14623092

p15(INK4b) in HDAC inhibitor-induced growth arrest.

Toshiaki Hitomi1, Youichirou Matsuzaki, Tomoya Yokota, Yuuki Takaoka, Toshiyuki Sakai.   

Abstract

Histone deacetylase (HDAC) inhibitors arrest human tumor cells at the G1 phase of the cell cycle and activate the cyclin-dependent kinase inhibitor, p21(WAF1/Cip1). However, several studies have suggested the existence of a p21(WAF1/Cip1)-independent molecular pathway. We report here that HDAC inhibitors, trichostatin A (TSA) and sodium butyrate, activate the p15(INK4b) gene, a member of the INK4 gene family, through its promoter in HaCaT cells. Furthermore, we show that up-regulation of p15(INK4b) by TSA is associated with cell growth inhibition of HCT116 p21 (-/-) cells. Our findings suggest that p15(INK4b) is one of the important molecular targets of HDAC inhibitors.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14623092     DOI: 10.1016/s0014-5793(03)01186-4

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  18 in total

1.  Butyrate, an HDAC inhibitor, stimulates interplay between different posttranslational modifications of histone H3 and differently alters G1-specific cell cycle proteins in vascular smooth muscle cells.

Authors:  Omana P Mathew; Kasturi Ranganna; Frank M Yatsu
Journal:  Biomed Pharmacother       Date:  2010-12       Impact factor: 6.529

2.  Histone deacetylase inhibitor belinostat represses survivin expression through reactivation of transforming growth factor beta (TGFbeta) receptor II leading to cancer cell death.

Authors:  Sanjib Chowdhury; Gillian M Howell; Carol A Teggart; Aparajita Chowdhury; Jonathan J Person; Dawn M Bowers; Michael G Brattain
Journal:  J Biol Chem       Date:  2011-07-08       Impact factor: 5.157

3.  Pulse inhibition of histone deacetylases induces complete resistance to oxidative death in cortical neurons without toxicity and reveals a role for cytoplasmic p21(waf1/cip1) in cell cycle-independent neuroprotection.

Authors:  Brett Langley; Melissa A D'Annibale; Kyungsun Suh; Issam Ayoub; Aaron Tolhurst; Birgül Bastan; Lichuan Yang; Brian Ko; Marc Fisher; Sunghee Cho; M Flint Beal; Rajiv R Ratan
Journal:  J Neurosci       Date:  2008-01-02       Impact factor: 6.167

4.  Suberoylanilide hydroxamic acid is effective in preclinical studies of medulloblastoma.

Authors:  Susan E Spiller; Ali C Ravanpay; Andrew W Hahn; James M Olson
Journal:  J Neurooncol       Date:  2006-04-28       Impact factor: 4.130

5.  "Combination-oriented molecular-targeting prevention" of cancer: a model involving the combination of TRAIL and a DR5 inducer.

Authors:  Tatsushi Yoshida; Mano Horinaka; Toshiyuki Sakai
Journal:  Environ Health Prev Med       Date:  2010-01-06       Impact factor: 3.674

6.  INK4 Family -A promising target for 'gene-regulating chemoprevention' and 'molecular-targeting prevention' of cancer.

Authors:  Youichirou Matsuzaki; Toshiyuki Sakai
Journal:  Environ Health Prev Med       Date:  2005-03       Impact factor: 3.674

7.  Characterization of the regulation and function of zinc-dependent histone deacetylases during rodent liver regeneration.

Authors:  Jiansheng Huang; Emily Barr; David A Rudnick
Journal:  Hepatology       Date:  2013-05       Impact factor: 17.425

8.  HDAC3 is linked to cell cycle machinery in MiaPaCa2 cells by regulating transcription of skp2.

Authors:  G Schneider; M Reichert; D Saur; R Hamacher; R Fritsch; R M Schmid
Journal:  Cell Prolif       Date:  2007-08       Impact factor: 6.831

9.  A Phase I Protocol of Hydralazine and Valproic Acid in Advanced, Previously Treated Solid Cancers.

Authors:  Julie Bauman; Monte Shaheen; Claire F Verschraegen; Steven A Belinsky; M Houman Fekrazad; Fa-Chyi Lee; Ian Rabinowitz; Meera Ravindranathan; Dennie V Jones
Journal:  Transl Oncol       Date:  2014-04-17       Impact factor: 4.243

10.  Effect of vorinostat on INK4 family and HDACs 1, 2, and 3 in pancreatic cancer and hepatocellular carcinoma.

Authors:  Masumeh Sanaei; Fraidoon Kavoosi
Journal:  Res Pharm Sci       Date:  2021-05-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.